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http://linkinghub.elsevier.com/retrieve/pii/S0002929714003103 Abstract Spinocerebellar ataxias (SCAs) are a heterogeneous group of autosomal-dominant neurodegenerative disorders involving the cerebellum and 23 different genes. We mapped SCA38 to a 56 Mb region on chromosome 6p in a SCA-affected Italian family by whole-genome linkage analysis. Targeted resequencing identified a single missense mutation (c.689G>T [p.Gly230Val]) in ELOVL5. Mutation screening of 456 independent SCA-affected individuals identified the same mutation in two further unrelated Italian families. Haplotyping showed that at least two of the three families shared a common ancestor. One further missense variant (c.214C>G [p.Leu72Val]) was found in a French family. Both missense changes affect conserved amino acids, are predicted to be damaging by multiple bioinformatics tools, and were not identified in ethnically matched controls or within variant databases. ELOVL5 encodes an elongase involved in the synthesis of polyunsaturated fatty acids of the ω3 and ω6 series. Arachidonic acid and docosahexaenoic acid, two final products of the enzyme, were reduced in the serum of affected individuals. Immunohistochemistry on control mice and human brain demonstrated high levels in Purkinje cells. In transfection experiments, subcellular localization of altered ELOVL5 showed a perinuclear distribution with a signal increase in the Golgi compartment, whereas the wild-type showed a widespread signal in the endoplasmic reticulum. SCA38 and SCA34 are examples of SCAs due to mutations in elongase-encoding genes, emphasizing the importance of fatty-acid metabolism in neurological diseases.
Main Text
Spinocerebellar ataxias (SCAs) are autosomal-dominant neurological disorders with an average prevalence of 5-7 in 100,000 individuals. 1, 2 SCAs are phenotypically characterized by gait ataxia and incoordination of eye movements, speech, and hand movements and are usually associated with cerebellar atrophy. 3, 4, 5, 6 Their genetic bases are highly heterogeneous and only partially known. More than 30 SCAs have been mapped, and 23 genes have been identified, but in most countries 40%-50% of families lack a genetic diagnosis. 3, 7 On the basis of the type of mutation, three main categories of SCAs can be identified: (1) disorders of CAG-coding polyglutamine repeat expansions, which are the most prevalent forms and include SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17 (MIM 164400, 183090, 109150, 183086, 164500, and 607136, respectively); (2) We collected a large Italian family with seven members affected by a pure form of cerebellar ataxia (family SCA38-01-BS, Figure 1A) . The participants or an authorized representative provided written informed consent. The ethics committee of the Hospital of Brescia in Italy provided ethical approval.
All clinical evaluations included a full medical history and examination, estimation of the age of onset, observation of additional neurological signs, electroneuromyographic studies, and whenever possible, brain MRI and/or fluorodesoxyglucose positron emission tomography (FDG-PET) scans. Epstein-Barr-virustransformed lymphoblastoid cell lines were available for five affected individuals: subjects III-5 and III-10 from family SCA38-01-BS and subjects IV-8, IV-9, and IV-12 from family SCA38-02-CA.
Initially, CAG expansions within genes involved in SCA were excluded. Genome-wide linkage analysis was performed on seven affected individuals (II-6, III-1, III-3, III-6, III-10, IV-1, and IV-2) and three healthy relatives (III-4, III-11, and III-12) with the Illumina LINKAGE_12 microarray, containing 6,090 SNP markers with an average gap of 441 kb and 0.58 cM across the genome, according to the manufacturer's protocol.
Three regions showed suggestive genetic linkage with Z > 1.5 ( Figure S1A , available online): on chromosome 6, the region between rs560194 and rs2180419 (10.5-21.7 Mb) showed Z max = +2.3 and the region between rs159988 and rs7776325 (25.1-99.9 Mb) showed Z max = +2.8, and on chromosome 10, the region between rs10824792 and rs736594 (54.5-71.2 Mb) showed Z max = +1.7. In addition, nine regions presented with uninformative multipoint LOD scores ranging from −1.9 to +0.1; two of them overlapped with SCA25-and SCA28-associated loci ( Figure S1A ). 
(B) Microsatellite genotypes with haplotype reconstruction of family SCA38-01-BS. Arrows indicate recombination events in healthy subjects IV-3 and IV-4; these events define the minimal region (boxed). On the right, distances of the markers from the top of chromosome 6p are indicated in Mb. (C) Electropherograms of missense mutations c.214C>G (p.Leu72Val) and c.689G>T (p.Gly230Val). (D) The amino acid sequence alignment of a portion of the human ELOVL5 in various orthologs. The two changed amino acids are conserved through vertebrates.
Three regions showed suggestive genetic linkage with Z > 1.5 ( Figure S1A , available online): on chromosome 6, the region between rs560194 and rs2180419 (10.5-21.7 Mb) showed Z max = +2.3 and the region between rs159988 and rs7776325 (25.1-99.9 Mb) showed Z max = +2.8, and on chromosome 10, the region between rs10824792 and rs736594 (54.5-71.2 Mb) showed Z max = +1.7. In addition, nine regions presented with uninformative multipoint LOD scores ranging from −1.9 to +0.1; two of them overlapped with SCA25-and SCA28-associated loci ( Figure S1A ).
To confirm linkage and refine mapping, we further genotyped the above affected individuals and four additional family members (II-3, III-7, IV-3, and IV-4) for 21 microsatellite markers located on chromosome 6 (UCSC Genome Browser hg19 and Table S1 ). Healthy status of subjects IV-3 and IV-4 was ascertained by neurologic examination and a FDG-PET scan when they were 40 years of age.
A significant multipoint LOD score (Z max = +3.08) was found in a single region between markers D6S1610 and chr6_AC73.9 ( Figure S1B ). Haplotype analysis of the recombinant individuals restricted this locus, which we named SCA38 in agreement with the HUGO nomenclature, to a 56.2 Mb interval flanked by markers D6S276 (24.2 Mb) and D6S460 (80.4 Mb) on 6p22.2-q14.1 ( Figure 1B ).
Using custom array comparative genomic hybridization, we did not identify any deletions or duplications in this candidate region in the genomic DNA of subject III-7 from family SCA38-01-BS (custom design containing 3,700 probes between positions 50,854,000 and 76,107,000 Mb [hg19] on chromosome 6; ∼1 probe per 5.9 Kb; Agilent Technologies).
We performed targeted resequencing of all genes within the candidate region in subjects III-6 and III-10. Figures 1A-1C) . Two further changes were unlikely to be mutations ( Table S3) . We demonstrated segregation of the c.689G>T (p.Gly230Val) mutation with the disease in a total of 20 available affected subjects from families SCA38-01-BS, SCA38-02-CA, and SCA38-03-TO ( Figure 1A ). Both c.214C>G and c.689G>T were absent in dbSNP137, 1000 Genomes, and the NHLBI EVS (13,006 chromosomes) and in 800 chromosomes from healthy controls. The protein changes affect highly conserved amino acids in vertebrates and are predicted to be damaging by bioinformatics tools ( Figure 1D ; Table S4 ). Figures S1C and S2 ). For family SCA38-02-CA, sharing of the SNP haplotype might suggest a more ancient progenitor or two independent de novo c.689G>T mutations.
All affected individuals had common clinical features (Table 1) . Initial symptoms were truncal ataxia and gait disturbance with an onset at about 40 years (up to 51 years in family SCA38-04-FR). Gaze-evoked nystagmus was always associated. Symptoms progressed very slowly. During the disease course, affected individuals had been able to walk until 50 years of age; later, they needed a walking stick. Dysarthria, as well as limb ataxia, was progressively evident. In two cases, diplopia was observed. Mild to moderate axonal neuropathy was diagnosed in five subjects. Mild sensory complains were reported in four affected individuals. Arterial hypertension and type 2 diabetes were present in one affected subject each. Cognitive disturbances were not reported, but individual II-2 (with c.214C>G [p.Leu72Val]) had psychiatric problems.
Structural neuroimaging (MRI) revealed cerebellar atrophy without obvious brainstem involvement in the moderate-severe stages ( Figure 2A ). In mid disease stages, MRI was within the normal range, but brain FDG-PET scans showed clear-cut cerebellar hypometabolism ( Figure S3 ).
ELOVL5 belongs to a multigenic family of genes encoding elongases. These enzymes are located in the endoplasmic reticulum (ER) and synthesize very-long-chain fatty acids with more than 16 carbons. Each elongase has its own substrate specificity, but there is some functional overlap. 16 ELOVL5 is involved in the synthesis of PUFAs with more than 20 carbons of both the ω3 and ω6 series (double bond [C = C] at the third and sixth carbon atoms, respectively, from the end of the chain), 17, 18 as shown by Elovl5-knockout mice, which have decreased synthesis of arachidonic acid (AA, 20:4, ω6), eicosapentaenoic acid (EPA, 20:5, ω3), and docosahexaenoic acid (DHA, 22:6, ω3).
10
ELOVL5 mRNA showed ubiquitous expression in different human tissues and prominent expression in adult brain and lung ( Figure 2B ). We explored the protein localization pattern in the cerebellum of human and mouse control samples. In Purkinje cells, the protein localized to the soma and the proximal portion of the dendritic tree ( Figures 2C-2F ), strengthening the likelihood that disruption of this gene plays a role in the pathogenesis of SCA38.
To verify ELOVL5 activity, we quantified very-long-chain fatty acids in the serum of four affected subjects with the c.689G>T (p.Gly230Val) mutation. We detected a significantly decreased level of two PUFAs directly synthesized by ELOVL5: AA and DHA ( Figure 2G ).
Lipid metabolism is strictly regulated by feedback loops that control the synthesis of enzymes whenever the amount of their products is altered. In Elovl5-knockout mice, EPA and DHA reduction induces an increase in the nuclear form of the transcription factor sterol regulatory element binding protein 1c (SREBP-1c), 10 which is known to induce the expression of Elovl5 and several other lipogenic genes involved in fatty-acid and triglyceride synthesis. In lymphoblasts from affected individuals, ELOVL5 was significantly increased at both the mRNA level (2.0 ± 0.2, mean ± SEM, unpaired t test, p = 0.0011; Figure 2H ; Table S6 ) and the protein level (2.85 ± 0.4, mean ± SEM, unpaired t test, p = 0.0023; Figure 2I ; Figure S4A ). Moreover, we demonstrated increased expression at the mRNA level of ELOVL6 (MIM 611546), a typical SREBP-1c target gene (2.5 ± 0.1, mean ± SEM, unpaired t test, p = 0.0012, data not shown). Figure S3A) .
Figure 2. MRI Scans, ELOVL5 Expression, ELOVL5 Localization, and PUFA Serum Levels (A) MRI scans of an affected individual (III-10 in family SCA38-01-BS). Coronal, midsagittal, and horizontal sections are reported. Cerebellar atrophy with vermis involvement is shown; the cortex and brainstem are preserved. (B) The normal expression pattern of ELOVL5 in five human tissues, lymphoblastoid cells, and four brain areas (mean ± SD). ELOVL5 showed prominent expression in brain and lung. Gene expression was measured by quantitative PCR with FAM-labeled Universal ProbeLibrary LNA probes (Roche Diagnostics) ( Table S6). (C-F) Micrographs of sections of healthy human (C and E) and murine (D and F) cerebellar cortex immunostained with ELOVL5 antibody. Human cerebellar sections were obtained from paraffin-embedded tissues of postmortem brain derived from a healthy subject. Sections were incubated with ELOVL5 polyclonal antibody (C15621, diluted 1:400, AssaybIoTech) and counterstained with hematoxylin. Higher magnifications of sections of human and mouse cerebellar cortex are shown in (E) and (F), respectively. Note the similar labeling pattern of human and mouse Purkinje cells and the presence of numerous labeled cells in the white matter. Abbreviations are as follows: ml, molecular layer; PCl, Purkinje cell layer; gl, granular layer; and wm, white matter. Scale bars represent 200 μm (C), 80 μm (D), 50 μm (E), and 20 μm (F). (G) Fatty-acid analysis in serum isolated from whole blood of four affected individuals (III-10 in family SCA38-01-BS, IV-8 and IV-9 in family SCA38-02-CA, and III-3 in family SCA38-03-TO

Lanes 1 and 2 are affected individuals IV-8 and IV-9, respectively, of family SCA38-02-CA; lanes 3 and 4 are two healthy controls.
This loop is responsible for an accumulation of lipids in the Elovl5-knockout mouse liver, leading to hepatic steatosis. 10 Neither this feature nor other metabolic anomalies were evidenced in SCA38-affected individuals, suggesting that the wild-type ELOVL5 allele has a compensatory residual function. However, given the specific expression of ELOVL5 in Purkinje cells, a reduction in DHA and EPA synthesis might have an effect on the cerebellum, although Elovl5 ablation in mice does not display an overt neurologic phenotype, but this deserves further careful investigation. 10 Lipid metabolism plays an important role in pre-and postnatal development and normal functioning of the CNS, given that this organ has the highest lipid content after adipose tissue. Altered levels of lipid molecules, such as fatty acids, are demonstrated in the neuronal system of individuals affected by neurodegenerative diseases, mental disorders, stroke, and trauma.
A variety of other neurological diseases, particularly hereditary spastic paraplegias 19, 20, 21, 22, 23 and related diseases, 24 also have altered lipid metabolism, which confirms the importance of lipid homeostasis in brain membranes. In particular, knocking down the biosynthesis of gangliosides affects the composition of membranes on other lipid components. 25 Interestingly, activity of beta-glucosidase bile acid glucocerebrosidase was found to be altered in a complex phenotype characterized by spastic paraplegia with cerebellar ataxia (SPG46 [MIM 614409]). 21, 26 On the other hand, missense changes in ELOVL5 might lead to protein misfolding that alters the homeostasis of subcellular compartments. To verify ELOVL5 mislocalization, we prepared wild-type and mutant constructs containing the full-length human ELOVL5 cDNA in frame with a C-terminal HaloTag (pReceiver-M50, code U1147, GeneCopoeia). Point mutations c.214C>G and c.689G>T were introduced by PCR-induced mutagenesis (primers are listed in Table S7 ). Subcellular localization was studied by confocal microscopy in four different cell types (COS-7, SK-N-BE2, NIH/3T3, and HeLa cells) ( Figure 3 ; Figures S4B, S5, and S6).
Wild-type ELOVL5 mainly localized in the ER compartment, as expected by published data. 27 In contrast, p.Leu72Val and p.Gly230Val ELOVL5 had a less diffuse ER signal but did show perinuclear and polarized subcellular localization ( Figure 3A ; Figures S5A and S6A), consistent with an increase in the Golgi apparatus, as shown by the Golgi marker GM-130, a peripheral cytoplasmic protein tightly bound to the cis-Golgi membranes ( Figure 3B ; Figures S5B and S6B ). 28 The Golgi apparatus has a central role in the secretory pathway. It is expected that any alteration of the Golgi proteome would affect its homeostasis and consequently the anterograde or retrograde protein trafficking through it. The Golgi might also serve as the last quality-control checkpoint for correct protein conformation and activation of the unfolded protein response (UPR). 29, 30 In particular, the cis-Golgi might serve as a backup quality-control system to retain and send back misfolded proteins to the ER. 31 Misfolded ELOVL5 might escape ER control, accumulate in the Golgi, and lead to chronic activation of the UPR, as hypothesized for infantile hypophosphatasia (MIM 241500), which is caused by a p.Asn153Asp substitution in alkaline phosphatase, tissue-nonspecific isozyme. 32 The UPR induces apoptosis by distinct overlapping mechanisms, among which is the upregulation of the transcription factor C/EBP-homologous protein (CHOP) via the protein kinase RNA-like ER kinase. 33 In p.Gly230Val-transfected COS-7 cells, the amount of CHOP was significantly increased, and it was slightly enhanced in p.Leu72Val-tranfected cells ( Figure S7 ).
Overall, our data show that the p.Gly230Val substitution causes ELOVL5 mislocalization and might activate the UPR (although this point requires further investigation). The p.Leu72Val substitution might alter trafficking at the Golgi, in terms of both receiving material from the ER and recycling components back to the ER. 34 On the basis of our screening, SCA38 is a rare hereditary ataxia with an estimated incidence of <1% among European individuals affected by an autosomal-dominant ataxia. This figure is in agreement with other SCAs due to conventional mutations, where higher frequencies are generally associated with founder effects.
Analogous with other SCAs caused by conventional mutations, SCA38 has a pure cerebellar phenotype with a progression slower than that of polyglutamine expansions 3 and joins an emerging group of neurological diseases due to fatty-acids defects.
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